McKnight’s Long-Term Care News (12/27) reports, “Drugmakers Sanofi-Aventis US Inc. and Sanofi-Aventis US LCC will pay up to $109 million in a settlement over an alleged scheme to provide doctors with free units of its knee-injection drug Hyalgan [hyaluronate] in return for purchase of the treatment.” The move “which was announced Dec. 19, also settled claims that the Paris-based company reported an average sales price (ASP) that omitted the free units of the arthritis-related pain reliever between 2005 and 2009.”